Urinary Bladder Neoplasm
Conditions
Keywords
Urinary Bladder cancer, diagnosis, Cellvizio Dual Band
Brief summary
Bladder cancer is one of the most common cancer worldwide and the second most frequent urological cancer. The photodynamic diagnosis technique (PDD) currently used (Hexvix®) has improved tumor detection but with a high false positive rate. Indeed, the main limitation of the PDD is its lack of specificity, ranging from 35 to 66%. The association of this technique with new technologies such as the Cellvizio Dual Band featuring simultaneous dual wavelength illumination and detection, could improve the identification of tumoral lesions. The objective of this study is to demonstrate the efficacy of Cellvizio dual band technique for the diagnosis of tumors bladders.
Interventions
DEVICECellvizio dual band
Using fluorescence cytoscopy, lesions in the bladder will be resected. The samples will be immediately observed in order to keep the fluorescein effect under confocal microscopy (Cellvizio dual band). After confocal microscopy samples will be fixed in formalin and prepare for the pathologist that will confirm the diagnosis. The Cellvizio system can be used to observe a resected sample ex vivo, offering a cellular-level view of internal tissue. This technique allows the visualization of the microstructure of the tissue in real-time which may improve targeted sampling, provide earlier disease detection and help patient management. The Cellvizio system includes miniaturized optics, optical fiber bundles, high-speed scanning and advanced image processing components.
Sponsors
Lille Catholic University
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients having 18 years old or more * Patients with a bladder carcinoma and with indication of tumor resection under Hexvix procedure. * Patients giving consent to participate in the study
Exclusion criteria
-No consent to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determination of the nucleo-cytoplasmic ratio of cells | at inclusion | In order to perform comparison between benign versus malignant cytology, significant differences between cytoplasmic areas and nuclear areas will be determine to stablish a value of nucleo-cytoplasmic ratio |
Secondary
| Measure | Time frame |
|---|---|
| Number of neoplastic lesions identified by Cellvizio compared to number of lesions identified by pathology | through the study completion, an average of 6 months |
Countries
France
Outcome results
None listed